TickerFacts.

Company research / TGTX

TG Therapeutics, Inc. (TGTX)

Build a valuation ↗↓ Download CSV

SEC name TG THERAPEUTICS, INC. · CIK 0001001316 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, TG Therapeutics, Inc. reported revenue of $616.29M. Revenue grew 87.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $799.54M.

Key ratios (year ended 2025-12-31)

83.7%
Gross margin (computed)
20.0%
Operating margin
72.6%
Net margin
69.0%
Return on year-end equity
87.3%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-14

Headquarters locality: New York City · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$799.54M$616.29M$329.00M$233.66M$2.79M$6.69M$152.0K$152.0K$152.0K$152.0K$152.0K
Cost of Revenue$140.94M$100.71M$38.49M$14.13M$265.0K$790.0Kn/an/an/an/an/a
Gross Profit (computed)$658.60M$515.57M$290.52M$219.53M$2.52M$5.90Mn/an/an/an/an/a
R&D Expense$225.80M$160.22M$94.29M$76.19M$125.35M$222.58M$165.90M$154.18M$159.39M$102.53M$69.23M
Operating Income$136.33M$123.32M$41.93M$20.63M-$218.32M-$344.77M-$273.59M-$169.06M-$174.40M-$118.71M-$78.97M
Depreciation & Amortization$123.0K$59.0K$68.0K$211.0K$303.0K$282.0Kn/an/an/an/an/a
EBITDA$136.45M$123.38M$42.00M$20.84M-$218.01M-$344.49Mn/an/an/an/an/a
Net Income$441.49M$447.18M$23.38M$12.67M-$223.81M-$348.10Mn/an/an/an/an/a
EPS (Diluted)n/a$2.77$0.15$0.09-$1.65-$2.63-$2.42n/an/an/an/a
Total Assets$1.64B$1.06B$577.69M$329.59M$193.57M$379.63M$625.64M$163.01M$83.62M$97.38M$54.78M
Total Liabilities$1.04B$415.23M$355.33M$169.09M$134.99M$142.48M$106.29M$124.40M$59.58M$30.39M$18.91M
Long-Term Debtn/an/an/a$100.40M$71.14M$67.76M$29.89M$28.97Mn/an/an/a
Shareholders' Equity$604.08M$648.02M$222.36M$160.50M$58.59M$237.15Mn/an/an/an/an/a
Cash & Equivalents$482.57M$79.15M$179.89M$92.93M$102.30M$298.89M$553.44M$112.64M$41.96M$56.72M$25.03M
Operating Cash Flow$17.88M-$24.77M-$40.52M-$31.41M-$176.17M-$295.63M-$214.51M-$132.81M-$128.93M-$93.76M-$61.59M
Capital Expenditures$491.0K$214.0K$45.0K$0$14.0K$401.0K$357.0K$131.0K$90.0K$2.0K$344.0K
Free Cash Flow$17.39M-$24.99M-$40.56M-$31.41M-$176.18M-$296.04M-$214.86M-$132.94M-$129.01M-$93.76M-$61.93M
Shares Outstanding153.08M155.31M155.84M151.42M146.39M143.25M140.58M109.38M83.87M73.14M56.78M
Weighted Average Diluted Sharesn/a161.41M160.34M148.51M135.41M132.22M115.33Mn/an/an/an/a
EPS (Basic)n/a$3.10$0.16$0.09-$1.65-$2.63-$2.42n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView